Compound 14 is a promising novel EV71 capsid inhibitor with potent in vitro and in vivo antiviral activity for the potential treatment of Hand, Foot, and Mouth Disease.
Should not yet change clinical practice for enterovirus infections; leaves open whether this novel.
Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which can spread its infections to the central nervous and other systems with severe consequences. The viral caspid protein VP1 is a well-known target for antiviral efficacy because its occupancy by suitable compounds could stabilize the virus capsid, thus preventing uncoating of virus for RNA release. In this Letter, design, synthesis, and biological evaluation of novel anti-EV71 agents (aminopyridyl 1,2,5-thiadiazolidine 1,1-dioxides) are described. One of the most promising compounds ( 14 ) showed excellent antiviral activity against EV71 (EC 50 = 4 nM) and exhibited excellent in vivo efficacy in the EV71 infected mouse model.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: